Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04292288
Other study ID # H-19010297
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 1, 2019
Est. completion date January 1, 2028

Study information

Verified date February 2024
Source Rigshospitalet, Denmark
Contact Martin Blomberg Jensen
Phone +4535453545
Email blombergjensen@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Today, there is an increased use of non-medical, invasive cosmetic treatments globally without sufficient awareness of possible health risks. A particular problem is young men injecting large amounts of paraffin oil into skeletal muscles especially on upper arms and chest to increase the visible size of the muscles. Several case reports have suggested that intramuscular injection of paraffin oil induces foreign body reaction and granuloma formation and subsequently hypercalcemia. Our hypothesis is that increased generation of activated vitamin D (1,25(OH)2D3) in the marcrophages may be responsible for the persistent hypercalcemia. Now trhe investigators want to include a large group of men who injected 100-10.000 ml paraffin oil to identify risk factors for developing hypercalcemia and try to understand the pathogenesis of the disease. Additionally, granuloma tissue from selected patients will be cultured ex vivo to investigate whether they produce 1,25(OH)2D3 or PTHrP and to test which drugs can most effectively be used to lower calcium levels in these men. Subsequently, we will try to stratify the men according to the severity of the changes in calcium homeostasis as we suggest that this stratification will be the basis for future intervention trials


Description:

Today, there is an increased use of non-medical, invasive cosmetic treatments globally without sufficient awareness of possible health risks. A particular problem is young men injecting large amounts of paraffin oil into skeletal muscles especially on upper arms and chest to increase the visible size of the muscles. Several case reports have suggested that intramuscular injection of paraffin oil induces foreign body reaction and granuloma formation. The formation of granuloma probably precedes the marked hypercalcemia that often develops and appears to be difficult to treat. The largest study to date included 14 men and showed that practically all men developed serious hypercalcemia, but the etiology was unclear. Foreign body granulomas are like other granulomatous diseases such as Tuberculosis or sarcoidosis rich in macrophages, (ref) and it has been proposed that increased generation of activated vitamin D (1,25(OH)2D3) in the marcrophages may be responsible for the persistent hypercalcemia. Calcium homeostasis is tightly regulated primarily by vitamin D, Parathyroid hormone (PTH) and Fibroblast growth factor 23 (FGF23) that rapidly modifies intestinal absorption, renal excretion and calcium mobilization from the skeletal compartment in response to immediate changes in serum calcium (ref). Vitamin D (cholecalciferol) is normally formed by UV-B radiation of the skin and requires two enzymatic reactions before it can bind and activate the vitamin D receptor (VDR). Conversion of cholecalciferol to 25-hydroxydvitamin (25OHD) is the first activation step; it is un-regulated and generally exerted by the hepatic CYP2R1. 25OHD is not biologically active and must undergo 1-alpha hydroxylation by renal CYP27B1 to form the active metabolite 1,25(OH)2D3. The main actions of 1,25(OH)2D3 is to promote calcium and phosphate absorption and decrease calcium excretion until inactivated by CYP24A1. 1,25(OH)2D3 is also a powerful inhibitor of PTH and inducer of FGF23, which ensures an important feedback-loop to maintain an adequate vitamin D status (ref). PTH which is a potent inducer of CYP27B1, mobilizes calcium and phosphate from the skeleton and increases phosphate excretion. In contrast, FGF23 that inhibits CYP27B1, induces the in-activating CYP24A1 and promotes phosphate excretion. Almost all organs has the ability to activate, respond to, and inactivate vitamin D because CYP27B1, VDR and CYP24A1 are expressed also in most non-renal tissues. However, regulation of CYP27B1 and CYP24A1 is strikingly different in these organs where high intracellular levels of 1,25(OH)2D3 activates VDR that induces transcription of CYP24A1 and thereby increases in-activation to restore normal intracellular levels of all vitamin D metabolites. This autoregulatory control of vitamin D metabolites secures under normal circumstances that high concentrations of 1,25(OH)2D3 are not released into circulation. Regulation of vitamin D homeostasis is different in the macrophages present in granulomas because they retain a splice variant of CYP24A1 that is not upregulated in response to high 1,25(OH)2D3 levels, which in part explains the increased release of 1,25(OH)2D3 in granulomatosis disease. Another important issue is aberrant regulation of CYP27B1 in macrophages, which is induced by inflammatory signals such as interleukin-2 and TNF-alpha rather than PTH. Previous case reports have detected CYP27B1 expression in granuloma tissue by immunohistochemistry. However, these findings have to our knowledge never been corroborated by a more comprehensive analysis of enzyme activity and a recent study questioned the etiology because most men with granulomas had normal levels of 1,25(OH)2D3 in serum (ref). In the present study the investigators want to include a large group of men who injected 100-10.000 ml paraffin oil to identify risk factors for developing hypercalcemia and try to understand the pathogenesis of the disease. Additionally, granuloma tissue from selected patients will be cultured ex vivo to investigate whether they produce 1,25(OH)2D3 or PTHrP and to test which drugs can most effectively be used to lower calcium levels in these men. Subsequently, elucidate whether it is possible to stratify the men according to the severity of the changes in calcium homeostasis as such a stratification may be required prior to and form the basis for future intervention trials


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date January 1, 2028
Est. primary completion date January 1, 2026
Accepts healthy volunteers
Gender Male
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - previous injection of paraffin oil into the body - Exclusion Criteria: - inability to walk - inability to understand the consequences of inclusion - incurable cancer disease

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Biochemical observational
no intervention - observational

Locations

Country Name City State
Denmark Herlev Hospital Herlev

Sponsors (2)

Lead Sponsor Collaborator
Martin Blomberg Jensen Herlev Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hypercalcemia the number of men with elevated ionized calcium (above 1.32 mmol/l) determined 2-10 years after paraffin oil injection (first visit)
Primary production of 1,25OHD3 production of 1,25OHD3 determined in media from granuloma tissue culture compared with kidney culture by ELISA platform ex vivo culture experiments of human granuloma tissue for 48 to 72 hours
Secondary hypercalciuria calcium excretion determined by spot or 24 hour urine determined 2-10 years after paraffin oil injection
Secondary change in serum 1,25OH2D3 differences in calcitriol production or conversion rate 1,25OH2D3/25OHD that reflects how active the enzyme is determined 2-10 years after paraffin oil injection (first visit)
Secondary nephrolithiasis obtained by interview -anamnesis and preferably supported by jorunal of CT report on nephrolithiasis determined 2-10 years after paraffin oil injection (first visit)
Secondary Overall change in calcium homeostasis changes in calcium, PTH, alkaline phosphatase and 1,25OHD depending on oil injected, varm/cold determined 2-10 years after paraffin oil injection (first visit)
Secondary inflammatory response changes in inflammatory markers IL2R, ferritin, ACE determined 2-10 years after paraffin oil injection (first visit)
Secondary Bone formation and resorption Serum levels of alkaline phosphatase, C-terminal telopeptide of type I collagen (CTX-I) and N-terminal propeptide of type I procollagen (PINP) determined 2-10 years after paraffin oil injection (first visit)
Secondary renal function change in GFR, creatinine, Urea determined 2-10 years after paraffin oil injection (first visit)
Secondary calciphylaxis risk determined by Calcium - phosphate product determined 2-10 years after paraffin oil injection (first visit)
Secondary Suppressed PTH PTH lower than lower reference (2) determined 2-10 years after paraffin oil injection (first visit)
Secondary suppression of 1,25OHD3 production production of 1,25OHD3 released into the media from granuloma culture suppressed by different treatments in vitro ex vivo culture experiments of human granuloma tissue exposed to treatments for 48 and 72 hours
Secondary production of PTHrP PTHrP production in granuloma determined by ELISA platform ex vivo culture experiments of human granuloma tissue for 48 and 72 hours
See also
  Status Clinical Trial Phase
Withdrawn NCT02711059 - Insulin Resistance in Primary Hyperparathyroidism N/A
Recruiting NCT05585593 - Registry for Hypoparathyroidism Wuerzburg
Terminated NCT01725113 - Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Phase 4
Completed NCT01460030 - An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism Phase 3
Completed NCT00325104 - Cinacalcet to Treat Familial Primary Hyperparathyroidism Phase 3
Recruiting NCT03935984 - Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity Phase 4
Withdrawn NCT01329666 - Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D Phase 2/Phase 3
Completed NCT00891813 - Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Phase 4
Completed NCT00674154 - Effect of Vitamin D Treatment in Primary Hyperparathyroidism Phase 2/Phase 3
Completed NCT04299425 - Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy N/A
Completed NCT00975221 - Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy Phase 3
Withdrawn NCT03516747 - Preoperational Fine Needle Aspiration of Pathological Parathyroid Gland N/A
Completed NCT00485706 - Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients N/A
Recruiting NCT01647503 - Differentially Expressed Proteins in Sporadic Parathyroid Tumors N/A
Completed NCT01042626 - Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects N/A
Not yet recruiting NCT01021280 - Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome N/A
Not yet recruiting NCT01226810 - The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration N/A
Terminated NCT00415584 - Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients Phase 1/Phase 2
Completed NCT00581828 - Does Treatment of Hypovitaminosis D Increase Calcium Absorption? Phase 4
Completed NCT00126386 - Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community N/A